Reproductive traits of polycystic ovary syndrome in female rhesus monkeys

TANG Xiang-Hui1,*, CAO Yue-Ling2, YANG Ze-Xing2, ZHAO Fu-Xian2

(1. Kunming Institute of Zoology, the Chinese Academy of Sciences, Kunming 650223, China; 2. The Fourth Affiliated Hospital of Kunming Medical College, Kunming 650021, China)

Abstract: The objective of this study was to set up a rhesus monkey model of polycystic ovary syndrome (PCOS), which is globally prevalent among reproductive-aged human women, and to understand the reproductive traits of PCOS female monkeys. Six adult female rhesus monkeys aged 6–10 a, were divided into a PCOS group and a control group. The PCOS group were given two cycles of subcutaneous injections of propionic acid testosterone (PAT), 3.5 mg/kg body weight, on day 1, day 3, and day 5 of the menstrual cycle, respectively, and then given muscle injections of human chorionic gonadotropin (HCG), 350 IU/kg body weight, on day 7, day 9, and day 11, respectively. Results showed that high levels of serum LH and T [(5.35±0.17) IU/L and (7.58±0.14) ng/mL, respectively], and a high ratio value of LH/FSH (5.35/1.30=4.12) were observed in the PCOS group. No significant differences were found in serum FSH, E2, and P in the PCOS group compared with those of the control. Polycystic ovaries in the PCOS monkeys were recorded by live ultrasound. The blastocysts rates of the PCOS vs. the control were 23.53% vs. 66.67%, and there was a significant difference between the two groups. This study shows that PAT coupled with HCG can induce PCOS in rhesus monkeys in the short term. The reproductive features of PCOS monkeys were similar to those of PCOS patients.

Key words: PCOS; Rhesus monkey; Reproduction; Controlled ovary stimulation
Polycystic ovary syndrome (PCOS) is a heterogeneous syndrome in women characterized by luteinizing hormone (LH) hypersecretion, ovarian hyperandrogenism, hyperinsulinemia from insulin resistance, and reduced fecundity. Given the 6.6% estimated prevalence of PCOS in reproductive-aged women in the United States (i.e., at least 4 million affected women), the annual economic burden of PCOS in the United States is at least $4.4 billion (Dumesic et al, 2007). In China, studies have shown that the prevalence of PCOS in reproductive-aged women in Jinan city is 6.46% (Chen et al, 2005), and different types of menstruation have been recorded among 2,100 cases of the so-called ‘Rotterdam criteria’ PCOS patients, that is, amenorrhea (31.2%), menstrual thin (63.8%), and regular menstrual cycle (5%) (Xu et al, 2009). In addition, PCOS is prevalent among puberty aged females worldwide. Previous research on the clinical features of puberty PCOS between the Uygur ethnic and Han ethnic peoples in Xinjiang, China, showed that compared with normal women, there was no difference in the menarche in puberty aged PCOS patients, but abnormal menstruation was prevalent among the latter (Lin & Ding, 2008).

The etiology and pathophysiology of PCOS remains unclear. Thus, the treatments only scratch the surface of the problem and drugs are needed to ease the symptoms. As human reproduction is concerned, several morphological findings in PCOS patients implicate increased recruitment of growing follicles from the primordial follicle pool with the development of the polycystic ovaries. In PCOS, the growth of follicles is impaired at the 6–8 mm size when granulosa cells normally begin to express aromatase and convert androgens produced by LH-stimulated theca cells to estradiol (E2) in the presence of FSH (Gougeon, 1996; Jakimiuk et al, 1998). Unfortunately, experimental constraints on the use of human tissue for biomedical research limit our knowledge of PCOS origins and its developmental effects on human reproduction. Given the limitations in human studies, establishing a generally accepted PCOS animal model to help investigate the etiology, pathophysiology, and treatment of PCOS is needed.

Rhesus monkey provides unique insight into the pathophysiology of PCOS. Not only do female macaques closely resemble women in terms of genome (Blekhman et al, 2008), reproductive biology (Abbott et al, 2004; Jimenez et al, 2005; Tarantal, 1992; Tarantala & Gargosky 1995; Tarantal et al, 1997), metabolic physiology (Wagner et al, 2006), and aging (Lee et al, 1995; Wu et al, 2005), they also exhibit PCOS-like traits spontaneously (Arifin et al, 2008) as well as following experimentally-induced androgen excess during early or late gestation (Abbott et al, 1998; 2005) or after acute exposure to androgen excess in adulthood (Vendola et al, 1998). Such spontaneous and experimentally-induced PCOS-like traits are unparalleled to date in other species, providing an important model for human disease (Abbott et al, 2006; Rosenfield, 2007).

Rhesus models of PCOS are beneficial for observation and evaluation and are especially suitable for research of reproductive dysfunction. Abbott et al (1998) found that female rhesus monkeys exposed in utero to levels of testosterone equivalent to those found in fetal males show many clinical and biochemical features of PCOS. However, the cost and long breeding cycle for producing the prenatally androgenized PCOS rhesus monkeys are not conducive to large-scale research. To establish a female rhesus monkey PCOS model in China, we focused on a short term procedure to produce a PCOS rhesus monkey and understand the reproductive traits of PCOS female monkey.

1 Materials and Methods

1.1 Hormones and chemicals

Unless stated otherwise, all chemicals were obtained from Sigma Chemical Co. (St. Louis, MO, USA).

1.2 Animals and hormone treatment

Six adult female monkeys (Macaca mulatta), 6-10 a, were used in this study and were maintained at the Kunming Primate Research Center, Kunming Institute of Zoology (KIZ) according to standard protocols (SCXK2008-0001). Three animals were placed in the PCOS group and the other three for control group. Rhesus macaques in all experiments were given standard primate chow with occasional supplementation of fresh fruit. The monkey chow formulation provides 75% of calories as carbohydrate, 10% as fat, and 15% as protein. Each female rhesus monkey (body weight 4–6 kg) was maintained in a cage (1,100 cm × 800 cm × 900 cm), which had a tap to provide filtered fresh water ad libitum. All animals were kept in a room with light control (12 h light/12 h dark) and a temperature of 23–25 °C with a relative humidity of 40%–55%. The animal care and use committee of KIZ approved all experiments and animal protocols.
The PCOS monkeys were developed as follows: Animals were given subcutaneous injections of 3.5 mg/kg body weight propionic acid testosterone (PAT) on day 1, day 3, and day 5 of the menstrual cycle, respectively, and then given muscle injections of 350 IU/kg body weight human chorionic gonadotropin (HCG) on day 7, day 9, and day 11, respectively. All PCOS rhesus monkeys were treated in this way for two consecutive menstrual cycles. The control animals were administered with normal saline each time.

1.3 Morphometry

At the end of the dosing periods, ultrasound and laparoscopy were performed on the monkeys under ketamine anesthesia to obtain a live picture of ovaries for morphometric analysis. Follicle size was determined by measurement of the largest cross-sectional diameter on the screen of the ultrasound. Ovaries were imaged abdominally using a Diasus ultrasound system (Dynamic Imaging Ltd., Livingston, Scotland, UK), equipped with a 10-22 MHz linear-array transducer.

1.4 Determination of serum hormones

Serum was collected for hormone measurement at the time of the subcutaneous injections of PAT and at the end of the dosing periods. Serum FSH, LH, estradiol, testosterone, and progesterone levels were measured by RIA according to the kit manual.

1.5 Controlled ovary stimulation (COS)

Treatment with recombinant human FSH (rhFSH; Gonal-F; Laboratories Serono SA, Aubonne, Switzerland) was initiated on day 3 of the menstrual for both PCOS and control monkeys. Vaginal bleeding was monitored daily to detect the onset of menses. Both groups received intramuscular (im) treatments of 18 IU rhFSH, twice daily, 10-12 h apart for eight consecutive days for controlled ovary stimulation, as described previously (Yang et al, 2009). Monkeys were then given 1000 IU HCG (Serono Laboratories, SA) intramuscularly on day 11 of the menstrual cycle. Oocytes retrieval was performed by laparoscopic follicular aspiration 32 to 35 h after hCG administration. Follicular contents were placed into HEPES-buffered TALP (modified Tyrode solution with albumin, lactate, and pyruvate) medium containing 0.3% bovine serum albumin (BSA) at 37 °C. Oocytes were stripped of cumulus cells by mechanical pipetting after brief exposure (<1 min) to hyaluronidase (0.5 mg/mL) to allow classification of nuclear maturity as metaphase I (MI; no germinal vesicle, no polar body) and metaphase II (MII; one polar body). Mature oocytes (MII) were placed in hamster embryo culture medium-10 (HECM-10) at 37 °C, 5% CO₂ humidified air until IVF.

1.6 IVF and embryo culture

To assess developmental competence of retrieved oocytes, freshly collected mature oocytes were inseminated as described previously (Yang et al, 2009). Briefly, hyperactivated spermatozoa and mature oocytes (MII) were co-incubated for 12-16 h at 37 °C in a humidified atmosphere of 5% CO₂. Fertilized oocytes exhibiting two pronuclei were cultured for embryonic development in 50 μL drops of HECM-10 containing 10% fetal bovine serum, covered with mineral oil, for up to 7 days at 37 °C in a humidified atmosphere of 5% CO₂. Progress of embryo growth was monitored daily using Nomarski optics (at ×200–×400 magnification) on a Nikon (Japan) Diaphot TMD microscope.

1.7 Statistical analysis

Results obtained were presented as the Mean±SD (unless stated otherwise). Statistical evaluations were performed with SPSS software (version 13.0; SPSS Inc., Chicago, IL). Values with P<0.05 were considered significantly different.

2 Results

2.1 Hormones change of PCOS monkeys

Serum hormones of PCOS monkeys are shown in Tab.1. Five serum hormones were measured in both the PCOS and control groups. After androgen administration, the PCOS monkeys showed different serum LH and testosterone (T) profiles compared with those of the control group and were characterized by high levels of serum LH and T (5.35±0.17) IU/L and (7.58±0.14) ng/mL, respectively. A high ratio value of LH/FSH (5.35/1.30=4.12) was observed in the PCOS group. There were no significant differences in the serum FSH, E₂, and P in the PCOS group compared with those of the control, although serum levels of these hormones were lower than that of the counterparts.

2.2 Ovary changes in PCOS monkeys

After establishment of the PCOS animal model, based primarily on the LH/FSH ratio value (LH/FSH>2), ultrasounds were performed for each animal for live observation of ovary status. A typical ovary image in the PCOS monkeys is shown in Fig. 1, in which more than five cysts were recorded under the condition of non-treatment. These cysts looked like stimulated follicles during the course of superovulation.
Table 1: Serum hormones of the PCOS and control monkeys

| Groups                  | No | FSH (IU/L)     | LH (IU/L)     | E2 (ng/L)    | T (ng/mL)    | P (ng/mL)    |
|-------------------------|----|----------------|---------------|--------------|--------------|--------------|
| PCOS before PAT injection | 3  | 1.58±0.12      | 1.41±0.11     | 26.38±0.14   | 2.10±0.11    | 0.79±0.14    |
| PCOS after HCG injection | 3  | 1.30±0.15      | 5.35±0.17*    | 19.52±0.12   | 7.58±0.14*   | 0.61±0.25    |
| Control                 | 3  | 1.57±0.11      | 1.42±0.09     | 28.17±0.16   | 2.14±0.08    | 0.83±0.11    |

Values are Mean±SD. * There is significant difference compared among the column (P<0.05).

Fig. 1: Typical polycystic ovary image in the PCOS monkey. More than five cysts in the right ovary were recorded by ultrasound. One cyst is labeled with the letter “A”. The overall size of the ovary in PCOS was larger than that of control at the same cycle period. Bar= 10 mm.

2.3 Response of PCOS monkeys to COS

Ovaries of PCOS monkeys showed a much stronger response to COS compared with those of the control. Fig. 2 shows a typical laparoscopic image of PCOS monkey ovaries over-stimulated after treatment of COS. However, fewer oocytes were retrieved from PCOS monkeys than the number of follicles recorded by ultrasound. This inconformity was not observed in the control animals where oocytes retrieved was in accordance with follicle numbers recorded by ultrasound on the day before oocytes retrieval (Tab. 2).

Table 2: Oocytes number retrieved from PCOS and their potential in vitro development

| Groups              | Follicles by ultrasound | Oocytes retrieved | Fertilized | 2-cell stage | 8-cell stage | Blastocyst |
|---------------------|-------------------------|-------------------|-----------|--------------|--------------|------------|
| PCOS                | 35                      | 17                | 11(64.71) | 11(64.71)    | 7(41.18)     | 4(23.53)*  |
| Control             | 21                      | 21                | 20(95.24) | 20(95.24)    | 16(76.19)    | 14(66.67)  |

Values are mean of each group. * There is significant difference within the column (P<0.05).

2.4 Developmental potential of oocytes from PCOS monkeys

Embryos derived from PCOS oocytes were compromised when they were cultured in vitro for blastocyst development. The blastocyst rates of PCOS vs. control were 23.53% vs. 66.67%, respectively, and there was significant difference between two groups (Tab. 2).

3 Discussion

This study shows that PAT coupled with HCG induced PCOS in rhesus monkeys in the short term, which recapitulated reproductive features of human PCOS, including PCO morphology, elevated serum androgen levels, high ratio value of LH/FSH (>2) and enlarged ovary size. The PCOS monkeys showed a strong response to controlled ovary stimulation, a characteristic in PCOS women that result in ovarian hyperstimulation (OHS) under the treatment of controlled ovary stimulation.

A neuroendocrine hallmark of PCOS women is enhanced LH hypersecretion from enhanced gonadotropin-releasing hormone (GnRH) pulsatility. Consequently, serum immuno- and bioactive LH levels are increased in about 70% of PCOS patients (Lobo, 1991), with elevated LH pulse amplitude and increased LH pulse frequency causing a two-three fold elevation in circulating LH versus FSH levels (Waldstreicher et al, 1988). The high ratio value of LH/FSH (5.35/1.30=4.12)
observed in the PCOS monkey was consistent with findings in PCOS humans. Moreover, elevated serum testosterone levels (7.58±0.14) ng/mL in PCOS monkeys plus polycystic ovaries scanned by ultrasound were fully compliant with the definition of PCOS, which is defined by the Rotterdam criteria as any two of the following three findings: clinical/biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries (The Rotterdam ESHRE/ASRM- sponsored PCOS consensus workshop group, 2004). Many PCOS patients undergoing in vitro fertilization (IVF) achieve a clinical pregnancy rate that is not comparable to that of similarly-treated normal women. These PCOS patients also have increased risk of implantation failure and pregnancy loss (Ludwig et al, 1999) as well as impaired oocyte fertilization unrelated to gross chromosomal abnormalities or nuclear maturation (Heijnen et al, 2006; Hwang et al, 2005; Kodama et al, 1995; Lu et al, 2006; Ludwig et al, 1999; Sengoku et al, 1997). Moreover, obese PCOS patients experience low oocyte fertilization and failure of embryos to implant in their own uterus or those of their surrogates (Cano et al, 1997), implicating and pathophysiology, especially in the reproductive dysfunction of PCOS humans.

In summary, all reproductive traits mentioned above demonstrated that PCOS monkeys can be developed by administration of PAT coupled with HCG in the short term. The reproductive features of PCOS monkeys were similar to those of PCOS patients. Further study is needed using this animal model to explore the etiology and pathophysiology, especially in the reproductive dysfunction of PCOS humans.

References:
Abbott DH, Dumesic DA, Eisner JR, Colman RJ, Kennitz JW. 1998. Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys [J]. Trends Endocrinol Metab, 9(2): 62-67.
Abbott DH, Foong SC, Barnett DK, Dumesic DA. 2004. Nonhuman primates contribute unique understanding to anovulatory infertility in women [J]. ILAR J, 45(2): 116-131.
Abbott DH, Barnett DK, Bruns CM, Schramm RD, Dumesic DA. 2005. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome [J]. Hum Reprod Update, 11(4): 357-374.
Abbott DH, Dumesic DA, Levine JE, Dunaif A, Padmanabhan V. 2006. Animal models and fetal programming of PCOS [M] // Azziz R, Nestler JE, Dewailly D. Contemporary Endocrinology: Androgen Excess Disorders in Women: Polycystic Ovary Syndrome and Other Disorders. 2nd ed. Totowa, NJ: Humana Press Inc., 259-272.
Arifin E, Shively CA, Register TC, Cline JM. 2008. Polycystic ovary syndrome with endometrial hyperplasia in a cynomolgus monkey (Macaca fascicularis) [J]. Vet Pathol, 45(4): 512-515.
Blekman R, Man O, Herrmann L, Boyko AR, Indap A, Kosiol C, Bustamante CD, Toshima KM, Przeworski M. 2008. Natural selection on genes that underlie human disease susceptibility [J]. Curr Biol, 18(12): 883-889.
Cano F, Garcia-Velasco JA, Millet A, Remohi J, Simón C, Pellicer A. 1997. Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women [J]. J Assist Reprod Genet, 14(5): 254-260.
Chen ZJ, Zhao JI, Zhou FR, Li Y, Zhao LX, Ma ZX. 2005. The primary investigation of prevalence of the polycystic ovary syndrome in general Han ethnic women in Jinan city [J]. Prog Obstet Gynecol, 16(4): 442-444. (in Chinese)
Dumesic DA, Abbott DH, Padmanabhan V. 2007. Polycystic ovary syndrome and its developmental origins [J]. Rev Endocr Metab Disord, 8(2): 127-141.
Gougeon A. 1996. Regulation of ovarian follicular development in primates: facts and hypothesis [J]. Endocr Rev, 17(2): 121-155.
Heijnen E, Eijkemans M, Hughes E, Laven J, Macklon N, Fauser B. 2006. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome [J]. Human Reprod Update, 12(1): 13-21.
Hwang JL, Seow KM, Lin YH, Hsieh BC, Huang LW, Chen HJ, Huang SC, Chen CY, Chen PH, Tseng CR. 2005. IVF versus ICSI in...
错，我们向作者和读者表示歉意。在此勘误发布以前，我们已更正了本刊网站上的电子版文件。

Sengoku K, Tamate K, Takuma N, Yoshida T, Goishi K, Ishikawa M.

Rosenfield RL. 2007. Identifying children at risk for polycystic ovary syndrome [J]. J Pediatr, 148(1): 41-47.

Wu JM, Zelinski MB, Ingram DK, Ottinger MA. 2005. Ovarian aging and menopause: current theories, hypotheses, and research models [J]. Exp Biol Med, 230(11): 818-828.

Xu XH, Tan YC, Shi YH, Wang B, Ju QX, Zheng QM, Hao CF, Chen ZJ. 2009. Different types of menstrual cycle and their significance in Chinese women diagnosed with polycystic ovary syndrome according to the Rotterdam consensus criteria [J]. Natl Med J China, 89(37): 2604-2606. (in Chinese)

Yang S, He X, Niu Y, Hildebrandt TB, Jewgenowc K, Goeritz F, Tang X, Chang Y, Zhou Q, Ji W. 2009. Ovarian response to gonadotropin stimulation in juvenile rhesus monkeys [J]. Theriogenology, 72(2): 243-250.